136 related articles for article (PubMed ID: 36840990)
1. Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.
Kato T; Ohara T; Suzuki N; Naya N; Fukao K; Tokuyama R; Muto S; Fukasawa H; Itai A; Matsumura KI
Bioorg Med Chem; 2023 Mar; 82():117215. PubMed ID: 36840990
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
Kato T; Ohara T; Suzuki N; Muto S; Tokuyama R; Mizutani M; Fukasawa H; Matsumura KI; Itai A
Bioorg Med Chem Lett; 2022 Mar; 59():128567. PubMed ID: 35063634
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure.
Kato T; Fukao K; Ohara T; Naya N; Tokuyama R; Muto S; Fukasawa H; Itai A; Matsumura KI
J Med Chem; 2023 Aug; 66(16):11428-11446. PubMed ID: 37552807
[TBL] [Abstract][Full Text] [Related]
4. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
[TBL] [Abstract][Full Text] [Related]
5. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
Kasuga J; Nakagome I; Aoyama A; Sako K; Ishizawa M; Ogura M; Makishima M; Hirono S; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Aug; 15(15):5177-90. PubMed ID: 17532641
[TBL] [Abstract][Full Text] [Related]
7. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
8. Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.
Fujieda H; Usui S; Suzuki T; Nakagawa H; Ogura M; Makishima M; Miyata N
Bioorg Med Chem Lett; 2007 Aug; 17(15):4351-7. PubMed ID: 17524643
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
[TBL] [Abstract][Full Text] [Related]
11. Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist.
Weigand S; Bischoff H; Dittrich-Wengenroth E; Heckroth H; Lang D; Vaupel A; Woltering M
Bioorg Med Chem Lett; 2005 Oct; 15(20):4619-23. PubMed ID: 16115765
[TBL] [Abstract][Full Text] [Related]
12. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
13. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
Bioorg Med Chem; 2008 Mar; 16(6):3321-41. PubMed ID: 18155554
[TBL] [Abstract][Full Text] [Related]
15. Advances and Challenges in Drug Design of PPARδ Ligands.
Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM
Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
18. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases.
Feng Z; Xiang J; Sun G; Liu H; Wang Y; Liu X; Feng J; Xu Q; Wen X; Yuan H; Sun H; Dai L
J Med Chem; 2023 Jun; 66(11):7331-7354. PubMed ID: 37243609
[TBL] [Abstract][Full Text] [Related]
20. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]